Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531352 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2532291 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2527437 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2533103 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL2527092 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL3919987 | 0.86 | ADRB2 (0.51) | SMN1; SMN2TSHRALDH1A1KDM4EMAPT | |
| SCHEMBL2560835 | 0.84 | AR (0.47) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2526160 | 0.84 | AR (0.51) | SMN1; SMN2TSHRARALDH1A1KDM4E | |
| SCHEMBL2525286 | 0.84 | CYP3A4 (0.47) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2528462 | 0.84 | MAPT (0.49) | SMN1; SMN2TSHRALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | SERENTRIX, LLC | 2019-03-19 | — | — | US | disclosed |
| EP-2552888-B1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | SERENTRIX LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX LLC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9216975-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Serentrix, LLC. (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102858742-B | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2015-05-27 | — | — | CN | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| CN-102858742-A | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2013-01-02 | — | — | CN | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2377850-A1 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Pharmeste S.r.l. (IT) | 2011-10-19 | — | — | EP | disclosed |
| US-8038010-B1 | Single piece edge protector for curved objects | ILLINOIS TOOL WORKS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011120604-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | PHARMESTE S.R.L. (IT) | 2011-10-06 | — | — | WO | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | SMN1; SMN2 4786/4885TSHR 940/4885AR 937/4885 |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | SMN1; SMN2 4541/4885TSHR 969/4885AR 1239/4885 |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | SMN1; SMN2 4117/4885TSHR 1950/4885AR 1188/4885 |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | TRPV1, TRPV5, TRPV3 | SMN1; SMN2 4117/4885TSHR 1950/4885AR 1188/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | SMN1; SMN2 4541/4885TSHR 969/4885AR 1239/4885 |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | SMN1; SMN2 4117/4885TSHR 1950/4885AR 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.